Lastly, as CD4+ T cells are known to constitute a substantial portion of TILs in invasive breast carcinoma after CD8+ T cells [30], we performed immunohistochemistry for CD4 and CD8 as a baseline comparison. This evidence concerns the gene CD4 and invasive breast carcinoma.